# Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

> **NCT03734588** · PHASE1,PHASE2 · COMPLETED · sponsor: **Spark Therapeutics, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Adeno-Associated Virus (AAV)
- Blood Coagulation Disorder
- Blood Coagulation Disorders, Inherited
- Coagulation Protein Disorders
- Factor VIII (FVIII)
- Factor VIII (FVIII) Deficiency
- Factor VIII (FVIII) Gene
- Factor VIII (FVIII) Protein
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Gene Therapy
- Gene Transfer
- Hematologic Diseases
- Hemorrhagic Disorders
- Recombinant
- Vector
- Inhibitors

## Interventions

- **GENETIC:** SPK-8016

## Key facts

- **NCT ID:** NCT03734588
- **Lead sponsor:** Spark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-30
- **Primary completion:** 2020-10-14
- **Final completion:** 2023-01-19
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03734588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03734588, "Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT03734588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*